ACCG-2671

September 8, 2026: Structure Therapeutics (NASDAQ: GPCR) reported positive updates for two obesity programs. ACCG-2671, an oral small-molecule dual amylin/calcitonin receptor agonist, showed in a Phase 1/2a SAD trial in 31 healthy participants without obesity an approximately 6-day half-life, rapid absorption, no serious adverse events, no drug-related discontinuations, no drug-induced liver injury, and exploratory target-engagement signals including 3.3% mean body weight loss at Day 24 after a single 10 mg dose and about a 60% reduction in CTX-1 on Day 2. GI events were dose-related at 5 mg and 10 mg. The 12-week MAD portion in participants with obesity has begun dosing, including daily/weekly regimens and a cohort on stable injectable GLP-1 therapy; topline data are expected in 1H 2027.

For aleniglipron, an oral GLP-1 receptor agonist, 72-week ACCESS OLE results showed weight loss of 11.6%, 14.4%, and 16.2% in prior 45 mg, 90 mg, and 120 mg groups titrated to 180 mg, with no observed plateau in the top two dose groups; more than one-third of participants in the 90 mg and 120 mg cohorts lost over 20% body weight. Fewer than 5% discontinued due to adverse events, and a 2.5 mg starting dose improved GI tolerability versus 5 mg. Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 enrollment is ongoing, with topline data expected in 2H 2028. Additional aleniglipron data are expected in Q4 2026 from Phase 2 body composition and T2DM trials and the Phase 1 SWITCH trial.